The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, explores the feasibility of hospital-based outpatient (HBO) management post-CAR-T therapy for patients with multiple myeloma (MM) and lymphoma. She highlights remote patient monitoring, outpatient management of cytokine release syndrome (CRS) with tocilizumab, and the incorporation of home visits by community paramedics. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
